Douglas Reed, M.D. joined Hatteras Venture Partners as a General Partner in early 2007. Prior to Hatteras, Doug has had 14 years of venture investing experience with two healthcare-focused funds, Vector Fund Management and S.R. One. He has been involved in venture investment transactions for over 25 healthcare and life science companies and currently serves as a director of CGI Pharmaceuticals, Digirad, Viamet Pharmaceuticals, and Phase Bioscience.

Beyond his venture investing experience, Doug has also served as Vice President of Business Development for two publicly-traded biotechnology companies, NPS Pharmaceuticals and GelTex (acquired by Genzyme).

Doug earned a BA in biology and an MD from the University of Missouri and an MBA from the Wharton School at the University of Pennsylvania. He is a board certified neuro-radiologist and has held faculty positions in the Department of Radiology at the University of Washington and Yale University.